{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:26:06Z","timestamp":1787286366893,"version":"build-2736575974"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pearl River Talent Plan\u2014Innovation and Entrepreneurship Team Introduction Project","award":["2023ZT10Y053"],"award-info":[{"award-number":["2023ZT10Y053"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC3504700"],"award-info":[{"award-number":["2023YFC3504700"]}]},{"name":"National Administration of Traditional Chinese Medicine","award":["ZYYCXTD-D-202403"],"award-info":[{"award-number":["ZYYCXTD-D-202403"]}]},{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome Project","award":["SKLKY2025C0004"],"award-info":[{"award-number":["SKLKY2025C0004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background\/Objectives: Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder for which antibody-based assays have limited sensitivity, particularly in double-seronegative MG (dsNMG), highlighting the need for complementary biomarkers. Given their roles in immune regulation, membrane integrity, and metabolic stress responses, lipids represent promising candidates for biomarker discovery. Methods: We designed a prospective case\u2013control study and systematically stratified 68 patients with myasthenia gravis (MG) according to clinical classification and autoantibody status. Using LC\u2013MS\/MS, we quantified 824 lipids in 136 serum samples collected from these patients and 68 healthy controls. The analyzed subtypes included ocular MG (OMG), generalized MG (GMG), acetylcholine receptor antibody-positive MG (AChR-MG), and dsNMG. Differential lipid analysis, correlation network construction, KEGG pathway enrichment, and multivariable logistic regression were performed. Diagnostic and subtype prediction models were developed using LASSO with 10 \u00d7 10 repeated cross-validation and interpreted using Shapley Additive exPlanations (SHAP) analysis. A longitudinal follow-up analysis was conducted to assess dynamic associations between lipid signatures and disease activity. Results: In total, 240 lipids were significantly altered in MG compared with controls. Lipids distinguishing GMG from OMG were enriched in ether lipid metabolism, necroptosis, and sphingolipid signaling pathways. AChR-MG and dsNMG shared lipid networks related to membrane remodeling and signaling regulation, whereas dsNMG exhibited marked elevations in acylcarnitines and bile acid-related metabolites, potentially reflecting a distinct phenotype characterized by altered energy metabolism. The lipid-based model achieved an AUC of 0.917 for distinguishing MG from controls, and AUCs of 0.77 and 0.71 for differentiating AChR-MG from dsNMG and GMG from OMG, respectively. Longitudinal analyses showed that SM(d18:1\/23:0) and Cer(d24:1\/18:0(2OH)) displayed dynamic changes consistent with disease activity. Conclusions: Serum lipidomics revealed subtype-specific metabolic features of MG, with stable disease-associated remodeling and dynamic sphingolipid changes potentially reflecting disease activity. By integrating systematic clinical and antibody-based subtype stratification with longitudinal follow-up, this study supports lipidomics as a complementary tool for precision diagnosis and disease stratification, particularly in antibody-negative dsNMG.<\/jats:p>","DOI":"10.3390\/metabo16080589","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:58:23Z","timestamp":1787126303000},"page":"589","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipidomic Profiling Reveals Distinct Molecular Signatures Across Clinical Subtypes of Myasthenia Gravis"],"prefix":"10.3390","volume":"16","author":[{"given":"Yufei","family":"Song","sequence":"first","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Dai","sequence":"additional","affiliation":[{"name":"Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), Hengqin 519031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9419","authenticated-orcid":false,"given":"Ruimin","family":"Tian","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Fang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Dong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyi","family":"Pang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China"},{"name":"Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), Hengqin 519031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: The changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lazaridis, K., and Tzartos, S.J. (2020). Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00212"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis\u2014Autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin","volume":"73","author":"Gallardo","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"He, D., Zhong, H., Jin, L., Chen, R., Wu, Z., Zhao, R., Huan, X., Yan, C., Song, J., and Xi, J. (2025). Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1578359"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"123162","DOI":"10.1016\/j.lfs.2024.123162","article-title":"Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis","volume":"358","author":"Lu","year":"2024","journal-title":"Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/NXI.0000000000000831","article-title":"High \u03ba free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis","volume":"7","author":"Alkalay","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","article-title":"Lipid metabolic reprogramming in tumor microenvironment: From mechanisms to therapeutics","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.pharmthera.2023.108411","article-title":"Lipid metabolism in Th17 cell function","volume":"245","author":"Kanno","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-025-00857-6","article-title":"Alzheimer\u2019s disease pathogenesis: Standing at the crossroad of lipid metabolism and immune response","volume":"20","author":"Wang","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1190607","DOI":"10.3389\/fimmu.2023.1190607","article-title":"Lipid metabolism and rheumatoid arthritis","volume":"14","author":"Lei","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41467-022-35663-x","article-title":"Lipid-induced transcriptomic changes in blood link to lipid metabolism and allergic response","volume":"14","author":"Dekkers","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11306-019-1571-9","article-title":"Beyond the antibodies: Serum metabolomic profiling of myasthenia gravis","volume":"15","author":"Blackmore","year":"2019","journal-title":"Metabolomics"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sikorski, P., Li, Y., Cheema, M., Wolfe, G.I., Kusner, L.L., Aban, I., and Kaminski, H.J. (2023). Serum metabolomics of treatment response in myasthenia gravis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0287654"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"119873","DOI":"10.1016\/j.cca.2024.119873","article-title":"Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring","volume":"562","author":"Sha","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1194\/jlr.D700041-JLR200","article-title":"Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics","volume":"49","author":"Matyash","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1194\/jlr.S120001025","article-title":"Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures","volume":"61","author":"Liebisch","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma","volume":"51","author":"Quehenberger","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jnc.15837","article-title":"Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis","volume":"165","author":"Zhang","year":"2023","journal-title":"J. Neurochem."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Almsherqi, Z.A. (2021). Potential Role of Plasmalogens in the Modulation of Biomembrane Morphology. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.673917"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12967-025-06341-5","article-title":"Comprehensive review of the expanding roles of the carnitine pool in metabolic physiology: Beyond fatty acid oxidation","volume":"23","author":"Xiang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1091\/mbc.e04-06-0458","article-title":"Cross talk between sphingolipids and glycerophospholipids in the establishment of plasma membrane asymmetry","volume":"15","author":"Kihara","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Meacci, E., and Garcia-Gil, M. (2019). S1P\/S1P Receptor Signaling in Neuromuscolar Disorders. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246364"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110564","DOI":"10.1016\/j.isci.2024.110564","article-title":"Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls","volume":"27","author":"Bhandage","year":"2024","journal-title":"iScience"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jcsm.12697","article-title":"Autoantibody of NRIP, a novel AChR-interacting protein, plays a detrimental role in myasthenia gravis","volume":"12","author":"Tsai","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00401-024-02754-6","article-title":"Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis","volume":"147","author":"Schroeter","year":"2024","journal-title":"Acta Neuropathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12944-025-02642-2","article-title":"Ceramide signaling in immunity: A molecular perspective","volume":"24","author":"Thakkar","year":"2025","journal-title":"Lipids Health Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tan-Chen, S., Guitton, J., Bourron, O., Le Stunff, H., and Hajduch, E. (2020). Sphingolipid Metabolism and Signaling in Skeletal Muscle: From Physiology to Physiopathology. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00491"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"San, P.P., and Jacob, S. (2023). Role of complement in myasthenia gravis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1277596"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ali, O., and Szab\u00f3, A. (2023). Review of Eukaryote Cellular Membrane Lipid Composition, with Special Attention to the Fatty Acids. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115693"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/00207454.2020.1738429","article-title":"Autophagy-deficiency in bone marrow mononuclear cells from patients with myasthenia gravis: A possible mechanism of pathogenesis","volume":"131","author":"Tang","year":"2021","journal-title":"Int. J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jov\u00e9, M., Mota-Martorell, N., Obis, \u00c8., Sol, J., Mart\u00edn-Gar\u00ed, M., Ferrer, I., Portero-Otin, M., and Pamplona, R. (2023). Ether Lipid-Mediated Antioxidant Defense in Alzheimer\u2019s Disease. Antioxidants, 12.","DOI":"10.3390\/antiox12020293"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/589\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:14:08Z","timestamp":1787285648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/8\/589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["metabo16080589"],"URL":"https:\/\/doi.org\/10.3390\/metabo16080589","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}